Hydroxy-PP-Me

• Description:

  Hydroxy-PP-Me is a selective CBR1 inhibitor with an IC50 of 759 nM. Hydroxy-PP-Me can inhibit serum starvation-induced apoptosis. Hydroxy-PP-Me can enhance the cytotoxic effects of Daunorubicin (HY-13062A) and As2O3 on tumor cells. Hydroxy-PP-Me can be used in the research of cancer such as leukemia[1][2].

• UNSPSC:

  12352005

• Target:

  Apoptosis; NADPH Oxidase; Reactive Oxygen Species (ROS)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/hydroxy-pp-me.html

• Purity:

  99.92

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  OC1=CC=CC(C2=CN(C(C)C)C3=C2C(NC)=NC=N3)=C1

• Molecular Formula:

  C16H18N4O

• Molecular Weight:

  282.34

• References & Citations:

  [1]Tanaka M, et al. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 2005 May;3 (5) :e128.|[2]Jang M, et al. Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide. Cancer Res. 2012 Aug 15;72 (16) :4214-24.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  833481-77-9